Background: Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder with diverse clinical manifestations and a high prevalence among women of reproductive age. Traditionally it is diagnosed using Rotterdam criteria,while recent 2023 guidelines propose the potential diagnostic use of serum Anti-Müllerian Hormone (AMH) and updated ultrasonographic parameters. This study aimed to assess the correlation between serum AMH levels and radiological markers of polycystic ovarian morphology (PCOM).
Methods: Our cross-sectional study was conducted on 100 women suspected to have PCOS. Serum AMH was estimated using chemiluminescent immunoassay. Transvaginal ultrasonography was performed by a single radiologist to assess ovarian volume (OV ?10 cc), follicle number per ovary (FNPO ?20), and follicle number per section (FNPS ?10). Statistical analysis was performed using SPSS v26. ROC (receiver operating curve) analysis was used to assess the diagnostic performance of AMH in detecting PCOM.
Results: Mean serum AMH levels were significantly higher in participants showing positive PCOM criteria (mean AMH: 7.7±4.4 ng/ml). The highest correlation was found between AMH and FNPO. ROC analysis revealed that AMH had an AUC of 0.85, with a cut-off value of 4.45 ng/ml showing the best sensitivity and specificity for detecting PCOM.
Conclusion: Serum AMH levels are strongly correlated with ultrasonographic PCOM features and may serve as a reliable, non-invasive diagnostic marker for PCOS in line with the 2023 guideline updates.
International Journal of Clinical Obstetrics and Gynaecology
Indexed in Index Copernicus
